Eflornithine hydrochloride is under clinical development by Panbela Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Eflornithine hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Eflornithine hydrochloride overview

Eflornithine Hydrochloride (Iwilfin) is alpha amino acid acts as an anti-neoplatic agent. It is formulated as tablets for oral route of administration. Iwilfin is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.

Eflornithine hydrochloride (CPP-1X) is under development for the treatment of STK11 mutated non-small cell lung cancer, refractory or relapsed neuroblastoma, gastric cancer, pancreatic cancer, metastatic castrate resistant prostate cancer (mCRPC), multiple myeloma and early onset type 1 diabetes mellitus. The drug candidate is administered through oral route in the form of tablet and high dose powder. CPP-1X acts by targeting ornithine decarboxylase. CPP-1X is a difluoromethylated ornithine (DFMO) compound that displays antiapoptotic, antiangiogenic and antiparasitic activity. It was also under development for the treatment of familial adenomatous polyposis.

Panbela Therapeutics overview

Panbela Therapeutics (Panbela), formerly Sun BioPharma Inc is a biopharmaceutical company. It develops disruptive therapeutics for the treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101. Its SBP-101 produces superior anti-tumour activity in human cancer cell lines and is used for the treatment of patients with pancreatic ductal adenocarcinoma, and pancreatitis. The company offers clinical trials and drug development services. It partners with institutions, cancer centres universities, and research centres for the development of drugs. Panbela is headquartered in Waconia, Minnesota, the US.

For a complete picture of Eflornithine hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 January 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.